186 related articles for article (PubMed ID: 24282288)
1. Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesis.
Jan Treda C; Fukuhara T; Suzuki T; Nakamura A; Zaini J; Kikuchi T; Ebina M; Nukiwa T
Carcinogenesis; 2014 Apr; 35(4):896-904. PubMed ID: 24282288
[TBL] [Abstract][Full Text] [Related]
2. Secretory leukocyte protease inhibitor inhibits expression of polymeric immunoglobulin receptor via the NF-κB signaling pathway.
Mikami Y; Iwase T; Komiyama Y; Matsumoto N; Oki H; Komiyama K
Mol Immunol; 2015 Oct; 67(2 Pt B):568-74. PubMed ID: 26239418
[TBL] [Abstract][Full Text] [Related]
3. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.
Devoogdt N; Hassanzadeh Ghassabeh G; Zhang J; Brys L; De Baetselier P; Revets H
Proc Natl Acad Sci U S A; 2003 May; 100(10):5778-82. PubMed ID: 12732717
[TBL] [Abstract][Full Text] [Related]
4. Temporal induction of secretory leukocyte protease inhibitor (SLPI) in odontoblasts by lipopolysaccharide and wound infection.
Choi BD; Jeong SJ; Wang G; Kim HJ; Kim BO; Hwang HK; Lim DS; Kim SH; Jeong MJ
J Endod; 2009 Jul; 35(7):997-1002. PubMed ID: 19567322
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model.
Lee NJ; Choi DY; Song JK; Jung YY; Kim DH; Kim TM; Kim DJ; Kwon SM; Kim KB; Choi KE; Moon DC; Kim Y; Han SB; Hong JT
Carcinogenesis; 2012 Dec; 33(12):2520-8. PubMed ID: 22907530
[TBL] [Abstract][Full Text] [Related]
6. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
Simpkins FA; Devoogdt NM; Rasool N; Tchabo NE; Alejandro EU; Kamrava MM; Kohn EC
Carcinogenesis; 2008 Mar; 29(3):466-72. PubMed ID: 17916899
[TBL] [Abstract][Full Text] [Related]
7. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.
Taggart CC; Cryan SA; Weldon S; Gibbons A; Greene CM; Kelly E; Low TB; O'neill SJ; McElvaney NG
J Exp Med; 2005 Dec; 202(12):1659-68. PubMed ID: 16352738
[TBL] [Abstract][Full Text] [Related]
8. Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells.
Choi BD; Jeong SJ; Wang G; Park JJ; Lim DS; Kim BH; Cho YI; Kim CS; Jeong MJ
Int J Mol Med; 2011 Oct; 28(4):527-34. PubMed ID: 21687932
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor.
Mulligan MS; Lentsch AB; Huber-Lang M; Guo RF; Sarma V; Wright CD; Ulich TR; Ward PA
Am J Pathol; 2000 Mar; 156(3):1033-9. PubMed ID: 10702419
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation.
Lentsch AB; Jordan JA; Czermak BJ; Diehl KM; Younkin EM; Sarma V; Ward PA
Am J Pathol; 1999 Jan; 154(1):239-47. PubMed ID: 9916938
[TBL] [Abstract][Full Text] [Related]
11. Secretory leukocyte protease inhibitor regulates human periodontal ligament cell production of pro-inflammatory cytokines.
Svensson D; Aidoukovitch A; Anders E; Jönsson D; Nebel D; Nilsson BO
Inflamm Res; 2017 Sep; 66(9):823-831. PubMed ID: 28597116
[TBL] [Abstract][Full Text] [Related]
12. The production of secretory leukocyte protease inhibitor by dendritic cells.
Vroling AB; Konijn T; Samsom JN; Kraal G
Mol Immunol; 2011 Jan; 48(4):630-6. PubMed ID: 21112636
[TBL] [Abstract][Full Text] [Related]
13. [Effects of secretory leukocyte protease inhibitor on the production of some cytokines and nitric oxide by murine peritoneal macrophages in response to lipopolysaccharide stimulation and M. avium complex infection].
Sano C; Shimizu T; Sato K; Ogasawara K; Tomioka H
Kekkaku; 1999 Jul; 74(7):563-70. PubMed ID: 10481411
[TBL] [Abstract][Full Text] [Related]
14. The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma.
Tse KP; Wu CS; Hsueh C; Chang KP; Hao SP; Chang YS; Tsang NM
Anticancer Res; 2012 Apr; 32(4):1299-307. PubMed ID: 22493362
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori-induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori-mediated diseases.
Wex T; Treiber G; Venerito M; Leodolter A; Peitz U; Kuester D; Hritz I; Krueger S; Roessner A; Malfertheiner P
Biol Chem; 2006 Jul; 387(7):893-901. PubMed ID: 16913839
[TBL] [Abstract][Full Text] [Related]
16. Characterization of secretory leukocyte protease inhibitor as an inhibitor of implantation serine proteinases.
Sharma N; Kaur J; Xu H; Zur Nieden N; Rancourt D
Mol Reprod Dev; 2008 Jul; 75(7):1136-42. PubMed ID: 18163438
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.
Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M
Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445
[TBL] [Abstract][Full Text] [Related]
18. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.
Sugino T; Yamaguchi T; Ogura G; Kusakabe T; Goodison S; Homma Y; Suzuki T
J Pathol; 2007 Jun; 212(2):152-60. PubMed ID: 17455170
[TBL] [Abstract][Full Text] [Related]
19. Secretory leukocyte protease inhibitor in cancer development.
Devoogdt N; Revets H; Ghassabeh GH; De Baetselier P
Ann N Y Acad Sci; 2004 Dec; 1028():380-9. PubMed ID: 15650263
[TBL] [Abstract][Full Text] [Related]
20. Activation of NF-κB by SOD2 promotes the aggressiveness of lung adenocarcinoma by modulating NKX2-1-mediated IKKβ expression.
Chen PM; Wu TC; Wang YC; Cheng YW; Sheu GT; Chen CY; Lee H
Carcinogenesis; 2013 Nov; 34(11):2655-63. PubMed ID: 23784082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
